ProShare Advisors LLC Has $2.20 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Posted by Defense World Staff on Apr 25th, 2023

ProShare Advisors LLC increased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating) by 6.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,700 shares of the biopharmaceutical company’s stock after buying an additional 2,448 shares during the quarter. ProShare Advisors LLC’s holdings in Halozyme Therapeutics were worth $2,202,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in HALO. US Bancorp DE increased its stake in shares of Halozyme Therapeutics by 2.1% in the 3rd quarter. US Bancorp DE now owns 11,305 shares of the biopharmaceutical company’s stock valued at $447,000 after purchasing an additional 236 shares during the last quarter. Dupont Capital Management Corp grew its position in Halozyme Therapeutics by 3.7% in the fourth quarter. Dupont Capital Management Corp now owns 10,644 shares of the biopharmaceutical company’s stock valued at $606,000 after acquiring an additional 382 shares during the last quarter. Hancock Whitney Corp grew its position in Halozyme Therapeutics by 4.2% in the third quarter. Hancock Whitney Corp now owns 9,597 shares of the biopharmaceutical company’s stock valued at $379,000 after acquiring an additional 386 shares during the last quarter. Cooper Financial Group grew its position in Halozyme Therapeutics by 6.3% in the fourth quarter. Cooper Financial Group now owns 7,378 shares of the biopharmaceutical company’s stock valued at $420,000 after acquiring an additional 436 shares during the last quarter. Finally, Inspire Investing LLC grew its position in Halozyme Therapeutics by 9.7% in the third quarter. Inspire Investing LLC now owns 5,201 shares of the biopharmaceutical company’s stock valued at $206,000 after acquiring an additional 460 shares during the last quarter. Institutional investors and hedge funds own 96.32% of the company’s stock.

Insider Buying and Selling

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 15th. The stock was sold at an average price of $48.39, for a total value of $483,900.00. Following the transaction, the senior vice president now directly owns 143,477 shares of the company’s stock, valued at $6,942,852.03. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Halozyme Therapeutics news, CEO Helen Torley sold 11,061 shares of the business’s stock in a transaction that occurred on Thursday, February 16th. The stock was sold at an average price of $49.26, for a total value of $544,864.86. Following the transaction, the chief executive officer now directly owns 633,666 shares of the company’s stock, valued at $31,214,387.16. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 15th. The shares were sold at an average price of $48.39, for a total value of $483,900.00. Following the completion of the transaction, the senior vice president now directly owns 143,477 shares in the company, valued at $6,942,852.03. The disclosure for this sale can be found here. Insiders have sold a total of 83,586 shares of company stock valued at $3,881,346 over the last ninety days. 2.30% of the stock is owned by company insiders.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $33.54 on Tuesday. The stock’s 50 day moving average is $40.62 and its 200 day moving average is $48.02. The company has a debt-to-equity ratio of 8.79, a current ratio of 5.65 and a quick ratio of 4.88. The firm has a market cap of $4.54 billion, a P/E ratio of 23.13, a P/E/G ratio of 0.51 and a beta of 1.22. Halozyme Therapeutics, Inc. has a one year low of $32.83 and a one year high of $59.46.

Halozyme Therapeutics (NASDAQ:HALO – Get Rating) last posted its quarterly earnings data on Tuesday, February 21st. The biopharmaceutical company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.01. The company had revenue of $181.50 million for the quarter, compared to analyst estimates of $186.07 million. Halozyme Therapeutics had a return on equity of 141.30% and a net margin of 30.62%. As a group, research analysts expect that Halozyme Therapeutics, Inc. will post 2.41 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on HALO shares. Berenberg Bank started coverage on Halozyme Therapeutics in a research report on Monday, March 27th. They issued a “buy” rating and a $58.00 target price on the stock. SVB Leerink cut Halozyme Therapeutics from an “outperform” rating to a “market perform” rating and set a $42.00 price target on the stock. in a report on Thursday, March 16th. JPMorgan Chase & Co. reduced their price target on Halozyme Therapeutics from $54.00 to $52.00 and set an “overweight” rating on the stock in a report on Thursday, February 23rd. SVB Securities cut Halozyme Therapeutics from an “outperform” rating to a “market perform” rating and set a $42.00 price target on the stock. in a report on Thursday, March 16th. Finally, StockNews.com initiated coverage on Halozyme Therapeutics in a report on Thursday, March 16th. They set a “hold” rating on the stock. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $56.33.

About Halozyme Therapeutics

(Get Rating)

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.